Mercaptamine-(Cysteamine)-Bitartrate

—

Anticipated · Australia

CYSTAGON mercaptamine

Anticipated · 🇦🇺 Australia

Anticipated shortage

Reading today’s signals…

✓ Can I substitute?

Yes — under S19A

TGA-approved overseas product

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

Oct 2026

Sponsor est. via TGA

Product attributes reference data we hold

Active ingredient (INN)	Mercaptamine-(Cysteamine)-Bitartrate
Brand names	CYSTAGON mercaptamine
Therapeutic category	Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper

Controlled substance	No

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Substitution pathways 🇦🇺 Australia · TGA

✓

Section 19A approval in force

The sponsor is closely controlling the supply. An overseas-registered product has been approved for supply under Section 19A. The approval holder, Pro Pharmaceuticals Group Pty Ltd, can be contacted for details on supply on 1300 077 674.

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.